Piramal Pharma Ltd Downgraded to Strong Sell Amid Weak Financials and Bearish Technicals

Quality Assessment: Weak Profitability and Debt Concerns

Piramal Pharma’s quality metrics have deteriorated, signalling caution for investors. The company’s average Return on Equity (ROE) stands at a mere 0.32%, indicating very low profitability relative to shareholders’ funds. This is compounded by a high Debt to EBITDA ratio of 3.83 times, which highlights a strained ability to service debt obligations. Such leverage levels increase financial risk, especially in a challenging operating environment.

Moreover, the company has reported negative results for three consecutive quarters. The Profit Before Tax excluding Other Income (PBT less OI) for Q3 FY25-26 plunged to a loss of ₹95.99 crores, a staggering decline of 2,577.2% compared to the previous four-quarter average. Similarly, the Profit After Tax (PAT) dropped by 755.0% to ₹-95.08 crores, with Earnings Per Share (EPS) at a low of ₹-1.03. These figures underscore the company’s operational difficulties and weak earnings quality.

Valuation: Fair but Discounted Relative to Peers

Despite the poor financial performance, Piramal Pharma’s valuation metrics suggest it is trading at a discount compared to its peers. The company’s Return on Capital Employed (ROCE) is modest at 2.7%, while the Enterprise Value to Capital Employed ratio stands at 2.1, indicating a fair valuation level. This discount could reflect market concerns about the company’s growth prospects and profitability challenges.

However, the stock price has underperformed the broader market significantly. Over the past year, Piramal Pharma’s share price declined by 15.56%, whereas the BSE500 index generated a positive return of 14.27%. This divergence highlights investor scepticism and the stock’s relative weakness within the Pharmaceuticals & Biotechnology sector.

Financial Trend: Negative Quarterly Results and Sluggish Growth

The financial trend for Piramal Pharma has been decidedly negative in recent quarters. The company’s net sales have grown at a modest annual rate of 7.96% over the last five years, which is relatively low for the pharmaceuticals industry. More concerning is the sharp decline in profitability, with operating profits falling by 372.9% over the past year.

Quarterly results reveal a troubling pattern. The latest quarter’s PBT less Other Income at ₹-95.99 crores and PAT at ₹-95.08 crores represent severe contractions compared to prior periods. This negative earnings trajectory has persisted for three consecutive quarters, signalling operational challenges and margin pressures.

In terms of stock returns, the company has underperformed the Sensex and broader market indices. While the Sensex delivered a 10.22% return over the last year, Piramal Pharma’s stock declined by 15.56%. Even over a three-year horizon, despite a cumulative return of 86.03%, the recent one-year underperformance weighs heavily on investor sentiment.

Technical Analysis: Shift to Bearish Momentum

The downgrade to Strong Sell is also driven by a deterioration in technical indicators. The technical grade has shifted from mildly bearish to outright bearish, reflecting weakening price momentum and negative market sentiment.

Key technical signals include:

• MACD: Weekly readings are bearish, with monthly indicators mildly bearish, suggesting downward momentum.
• Moving Averages: Daily moving averages are bearish, indicating the stock is trading below key support levels.
• Bollinger Bands: Both weekly and monthly bands show mildly bearish trends, signalling increased volatility with downward bias.
• KST (Know Sure Thing): Weekly KST is bearish, reinforcing the negative momentum.

Other indicators such as RSI and On-Balance Volume (OBV) show no clear signals, while Dow Theory presents a mildly bullish weekly trend but no monthly trend, reflecting mixed longer-term technical outlooks. The stock’s current price of ₹166.10 is closer to its 52-week low of ₹148.30 than its high of ₹241.00, underscoring the recent weakness.

Institutional Holdings and Market Position

Despite the negative outlook, Piramal Pharma maintains a relatively high institutional holding of 45.35%. Institutional investors typically possess greater analytical resources and may be positioned for a potential turnaround or value opportunity. However, the current strong sell rating and weak fundamentals suggest caution.

The company operates within the Pharmaceuticals & Biotechnology sector, which has seen mixed performance. While some peers have demonstrated robust growth and profitability, Piramal Pharma’s struggles with debt servicing and earnings contraction have placed it at a disadvantage.

Conclusion: Downgrade Reflects Comprehensive Weakness Across Parameters

The downgrade of Piramal Pharma Ltd to a Strong Sell rating by MarketsMOJO on 18 Feb 2026 is a reflection of multiple adverse factors. The company’s quality metrics reveal poor profitability and high leverage, while valuation remains fair but discounted due to weak growth prospects. Financial trends show sustained negative quarterly results and underperformance relative to the market. Technical indicators have shifted decisively to bearish, signalling further downside risk.

Investors should weigh these factors carefully, considering the company’s operational challenges and market sentiment. While institutional investors maintain a significant stake, the overall outlook remains cautious. Piramal Pharma’s current Mojo Score of 26.0 and Mojo Grade of Strong Sell underscore the need for prudence in portfolio allocation.

Only Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Start Today